Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03971409
Title Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hope Rugo, MD

triple-receptor negative breast cancer


Avelumab + PF-04518600

Avelumab + Utomilumab

Avelumab + Binimetinib

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.